These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 19791825

  • 1. Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks?
    Nurmohamed MT.
    Drugs; 2009 Oct 22; 69(15):2035-43. PubMed ID: 19791825
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
    Beresniak A, Baerwald C, Zeidler H, Krüger K, Neubauer AS, Dupont D, Merkesdal S.
    Clin Exp Rheumatol; 2013 Oct 22; 31(3):400-8. PubMed ID: 23464803
    [Abstract] [Full Text] [Related]

  • 3. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.
    Prescrire Int; 2009 Oct 22; 18(103):198-201. PubMed ID: 19882783
    [Abstract] [Full Text] [Related]

  • 4. [Non-TNF biologicals in the therapeutic strategy for rheumatoid arthritis].
    Wollenhaupt J, Krüger K.
    Z Rheumatol; 2010 Sep 22; 69(7):618-25. PubMed ID: 20703488
    [Abstract] [Full Text] [Related]

  • 5. New therapies for treatment of rheumatoid arthritis.
    Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P.
    Lancet; 2007 Dec 01; 370(9602):1861-74. PubMed ID: 17570481
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.
    Huoponen S, Aaltonen KJ, Viikinkoski J, Rutanen J, Relas H, Taimen K, Puolakka K, Nordström D, Blom M.
    PLoS One; 2019 Dec 01; 14(7):e0220142. PubMed ID: 31339961
    [Abstract] [Full Text] [Related]

  • 8. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis.
    Crnkic Kapetanovic M, Saxne T, Jönsson G, Truedsson L, Geborek P.
    Arthritis Res Ther; 2013 Oct 30; 15(5):R171. PubMed ID: 24286269
    [Abstract] [Full Text] [Related]

  • 9. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
    Gibbons LJ, Hyrich KL.
    BioDrugs; 2009 Oct 30; 23(2):111-24. PubMed ID: 19489652
    [Abstract] [Full Text] [Related]

  • 10. The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug.
    Navarro Coy NC, Brown S, Bosworth A, Davies CT, Emery P, Everett CC, Fernandez C, Gray JC, Hartley S, Hulme C, Keenan AM, McCabe C, Redmond A, Reynolds C, Scott D, Sharples LD, Pavitt S, Buch MH.
    BMC Musculoskelet Disord; 2014 Dec 23; 15():452. PubMed ID: 25539805
    [Abstract] [Full Text] [Related]

  • 11. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.
    Health Technol Assess; 2006 Nov 23; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [Abstract] [Full Text] [Related]

  • 12. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review.
    Rubbert-Roth A, Finckh A.
    Arthritis Res Ther; 2009 Nov 23; 11 Suppl 1(Suppl 1):S1. PubMed ID: 19368701
    [Abstract] [Full Text] [Related]

  • 13. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part II. Tocilizumab, Abatacept, Rituximab--drugs characterised by a different mechanism of action than TNF-alpha inhibitors].
    Swierkot J, Madej M.
    Pol Merkur Lekarski; 2011 Apr 23; 30(178):289-94. PubMed ID: 21595177
    [Abstract] [Full Text] [Related]

  • 14. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
    Vieira MC, Zwillich SH, Jansen JP, Smiechowski B, Spurden D, Wallenstein GV.
    Clin Ther; 2016 Dec 23; 38(12):2628-2641.e5. PubMed ID: 27889300
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
    Isaacs JD.
    Expert Opin Biol Ther; 2009 Dec 23; 9(12):1463-75. PubMed ID: 19916731
    [Abstract] [Full Text] [Related]

  • 16. Sequential use of biologic therapy in rheumatoid arthritis.
    Buch MH.
    Curr Opin Rheumatol; 2010 May 23; 22(3):321-9. PubMed ID: 20190641
    [Abstract] [Full Text] [Related]

  • 17. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.
    Salliot C, Dougados M, Gossec L.
    Ann Rheum Dis; 2009 Jan 23; 68(1):25-32. PubMed ID: 18203761
    [Abstract] [Full Text] [Related]

  • 18. [Effectiveness of biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model].
    Brodszky V.
    Orv Hetil; 2011 Jun 05; 152(23):919-28. PubMed ID: 21592952
    [Abstract] [Full Text] [Related]

  • 19. [Recent topics on new biological agents for treatment of rheumatoid arthritis].
    Saito K, Tanaka Y.
    Nihon Naika Gakkai Zasshi; 2008 Oct 10; 97(10):2418-23. PubMed ID: 19149039
    [No Abstract] [Full Text] [Related]

  • 20. Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis.
    Papagoras C, Voulgari PV, Drosos AA.
    Autoimmun Rev; 2010 Jun 10; 9(8):574-82. PubMed ID: 20433955
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.